Haemostatic drugs for traumatic brain injury
- 20 January 2010
- reference entry
- Published by Wiley
- No. 1,p. CD007877
Abstract
Background Traumatic brain injury (TBI) is a leading cause of death and disability. Intracranial bleeding is a common complication of TBI, and intracranial bleeding can develop or worsen after hospital admission. Haemostatic drugs may reduce the occurrence or size of intracranial bleeds and consequently lower the morbidity and mortality associated with TBI. Objectives To assess the effects of haemostatic drugs on mortality, disability and thrombotic complications in patients with traumatic brain injury. Search methods We searched the electronic databases: Cochrane Injuries Group Specialised Register (3 February 2009), CENTRAL (The Cochrane Library 2009, Issue 1), MEDLINE (1950 to Week 3 2009), PubMed (searched 3 February 2009 (last 180 days)), EMBASE (1980 to Week 4 2009), CINAHL (1982 to January 2009), ISI Web of Science: Science Citation Index Expanded (SCI‐EXPANDED) (1970 to January 2009), ISI Web of Science: Conference Proceedings Citation Index ‐ Science (CPCI‐S) (1990 to January 2009). Selection criteria We included published and unpublished randomised controlled trials comparing haemostatic drugs (antifibrinolytics: aprotinin, tranexamic acid (TXA), aminocaproic acid or recombined activated factor VIIa (rFVIIa)) with placebo, no treatment, or other treatment in patients with acute traumatic brain injury. Data collection and analysis Two review authors independently examined all electronic records, and extracted the data. We judged that there was clinical heterogeneity between trials so we did not attempt to pool the results of the included trials. The results are reported separately. Main results We included two trials. One was a post‐hoc analysis of 30 TBI patients from a randomised controlled trial of rFVIIa in blunt trauma patients. The risk ratio for mortality at 30 days was 0.64 (95% CI 0.25 to 1.63) for rFVIIa compared to placebo. This result should be considered with caution as the subgroup analysis was not pre‐specified for the trial. The other trial evaluated the effect of rFVIIa in 97 TBI patients with evidence of intracerebral bleeding in a computed tomography (CT) scan. The corresponding risk ratio for mortality at the last follow up was 1.08 (95% CI 0.44 to 2.68). The quality of the reporting of both trials was poor so it was difficult to assess the risk of bias. Authors' conclusions There is no reliable evidence from randomised controlled trials to support the effectiveness of haemostatic drugs in reducing mortality or disability in patients with TBI. New randomised controlled trials assessing the effects of haemostatic drugs in TBI patients should be conducted. These trials should be large enough to detect clinically plausible treatment effects.Keywords
This publication has 28 references indexed in Scilit:
- Recombinant activated factor VII use in the emergency departmentEmergency Medicine Journal, 2008
- Progression of Traumatic Intracerebral Hemorrhage: A Prospective Observational StudyJournal of Neurotrauma, 2008
- Predicting outcome after traumatic brain injury: practical prognostic models based on large cohort of international patientsBMJ, 2008
- Safety of rFVIIa in hemodynamically unstable polytrauma patients with traumatic brain injury: post hocanalysis of 30 patients from a prospective, randomized, placebo-controlled, double-blind clinical trialCritical Care, 2007
- Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia2007
- Prognosis and Clinical Trial Design in Traumatic Brain Injury: The IMPACT StudyJournal of Neurotrauma, 2007
- Improving the Evidence Base for Trauma Care: Progress in the International CRASH-2 TrialPLoS Clinical Trials, 2006
- Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia2003
- Basis of antifibrinolytic therapyJournal of Clinical Pathology, 1980
- Proteolytic enzyme activity in patients with severe head injury and the effect of a proteinase inhibitorActa Neurochirurgica, 1979